|
|
|
| home > pmps > summer 2003 > changing times for process automation in the pharmaceutical sector |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
For once the professional fortune tellers are in agreement - pharmaceuticals look set to provide a rare opportunity for significant growth in an otherwise difficult market for process automation suppliers over the coming years. This article will attempt to explain the reasons for this and looks at some of the latest technology available for use throughout the pharmaceutical industry.
According to a recent report from US-based pundits at the ARC Advisory Group, the global pharmaceutical and food and drink industries will provide the biggest growth opportunities for automation suppliers until at least 2006. The growth in the total automation market limped along at less than one per cent in 2000-2001 and ARC expects this to reach an average of just 3.4 per cent a year through to 2006. Larry O'Brien, ARC's Director of Research for the process industries, says: "In this environment of limited growth, the food and beverage and pharmaceutical industries will offer the strongest potential opportunity in the long term."
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
World Vaccine Congress
10-12 April 2012, Gaylord National Hotel and Convention Center, Washington, US
The 12th annual World Vaccine Congress Washington brings new scientific and business critical debate, discussion and solutions from the true global pioneers shaping vaccine R&D.
More info >> |
|
 |
News and Press Releases |
 |
Norwich Expands Capabilities for Phase I-III Clinical Trials
Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
More info >> |
|
|
